- $71.26m
- $66.44m
- $17.78m
- 54
- 19
- 32
- 27
Annual balance sheet for BioLargo, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 0.716 | 0.962 | 1.85 | 3.54 | 3.55 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.484 | 0.513 | 1.06 | 2.61 | 3.17 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 1.5 | 1.8 | 3.15 | 6.36 | 7.14 |
Net Property, Plant And Equipment | 0.401 | 0.514 | 1.15 | 1.75 | 3.19 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 4.94 | 3.02 | 4.86 | 8.21 | 10.5 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 3.54 | 1.37 | 1.58 | 2.71 | 2.65 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 1.08 | -1.63 | -0.02 | 1.36 | 1.66 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 3.86 | 4.65 | 4.88 | 6.84 | 8.85 |
Total Liabilities & Shareholders' Equity | 4.94 | 3.02 | 4.86 | 8.21 | 10.5 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |